Thomas Jefferson University

Jefferson Digital Commons
Department of Pediatrics Faculty Papers

Department of Pediatrics

2-16-2020

Long-Term Follow-up Posthematopoietic Stem Cell
Transplantation in a Japanese Patient with Type-VII
Mucopolysaccharidosis
Kenji Orii
Gifu University

Yasuyuki Suzuki
Gifu University

Shunji Tomatsu
Thomas Jefferson University

Tadao Orii
Gifu University
Follow
this Fukao
and additional works at: https://jdc.jefferson.edu/pedsfp
Toshiyuki

GifuPart
University
of the Pediatrics Commons

Let us know how access to this document benefits you
Recommended Citation
Orii, Kenji; Suzuki, Yasuyuki; Tomatsu, Shunji; Orii, Tadao; and Fukao, Toshiyuki, "Long-Term
Follow-up Posthematopoietic Stem Cell Transplantation in a Japanese Patient with Type-VII
Mucopolysaccharidosis" (2020). Department of Pediatrics Faculty Papers. Paper 92.
https://jdc.jefferson.edu/pedsfp/92
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Pediatrics Faculty Papers by an authorized administrator of the Jefferson
Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

diagnostics
Case Report

Long-Term Follow-up Posthematopoietic Stem Cell
Transplantation in a Japanese Patient with
Type-VII Mucopolysaccharidosis
Kenji Orii 1, *, Yasuyuki Suzuki 2 , Shunji Tomatsu 1,3,4 , Tadao Orii 1 and Toshiyuki Fukao 1
1
2
3
4

*

Department of Pediatrics, Gifu University Graduate School of Medicine, Yanagido 1-1, Gifu 501-1194, Japan;
stomatsu@nemours.org (S.T.); tomatsushunji@gmail.com (T.O.); toshi-gif@umin.net (T.F.)
Medical Education Development Center, Gifu University, Yanagido 1-1, Gifu 501-1194, Japan;
ysuz@gifu-u.ac.jp
Nemours/Alfred I. Dupont Hospital for Children, 1600 Rockland Rd., Wilmington, DE 19803, USA
Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA 19144, USA
Correspondence: kenjior-gif@umin.ac.jp; Tel.: +81-58-230-6386

Received: 15 January 2020; Accepted: 13 February 2020; Published: 16 February 2020




Abstract: The effectiveness of hematopoietic stem cell transplantation (HSCT) for type-VII
mucopolysaccharidosis (MPS VII, Sly syndrome) remains controversial, although recent studies have
shown that it has a clinical impact. In 1998, Yamada et al. reported the first patient with MPS VII,
who underwent HSCT at 12 years of age. Here, we report the results of a 22-year follow-up of that
patient post-HSCT, who harbored the p.Ala619Val mutation associated with an attenuated phenotype.
The purpose of this study was to evaluate changes in physical symptoms, the activity of daily living
(ADL), and the intellectual status in the 34-year-old female MPS VII patient post-HSCT, and to prove
the long-term effects of HSCT in MPS VII. Twenty-two years after HSCT, the β-glucuronidase activity
in leukocytes remained at normal levels, and urinary glycosaminoglycan excretion was reduced
and kept within normal levels. At present, she is capable of sustaining simple conversation, and
her intellectual level is equivalent to that of a 6-year-old. She can walk alone and climb upstairs by
holding onto a handrail, although she feels mild pain in the hip joint. The cervical vertebrae are fused
with the occipital bone, causing dizziness and light-headedness when the neck is bent back. Overall,
her clinical condition has been stabilized and kept well for long-term post-HSCT, indicating that
HSCT is a therapeutic option for MPS VII.
Keywords: mucopolysaccharidoses; Sly syndrome; activity of daily living; hematopoietic stem
cell transplantation

1. Introduction
Mucopolysaccharidosis VII (MPS VII; Sly syndrome; OMIN#253220) is an autosomal recessive
lysosomal storage disorder (LSD) that is caused by a deficiency of the activity of β-glucuronidase
(GUSB: β-d-glucuronoside Enzyme Commission (EC) number: 3.2.1.31; GUSB: MIM611499)[1,2].
The deficiency of this enzyme leads to the accumulation of specific glycosaminoglycans (GAGs),
i.e., chondroitin sulfate (CS), dermatan sulfate (DS), and heparan sulfate (HS). This disease was first
clinically described by Sly et al. in a patient whose features were similar to those of the patient described
here [1]. Although clinical phenotypes are widely seen from the most severe phenotype with hydrops
fetalis to the attenuated phenotype without central nervous system (CNS) involvement, patients with
MPS VII often show short stature, hepatosplenomegaly, progressive skeletal deformities of the thorax
and spine, and frequent symptomatic pulmonary infections before 2 years of age. Intellectual disability
also appears at 2 years of age. Montaño et al. reported that 34% of patients were diagnosed prenatally
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or below 1 year of age, 16% from 1 year to 3 years of age, 11% from 3 years to 5 years of age, 20% from
5 years to 10 years of age, and 12% over 10 years of age [3]. Thirteen patients with MPS VII who had
the infantile form with a history of hydrops fetalis and survived childhood showed various clinical
manifestations from mild to severe [3]. Radiologic changes of “dysostosis multiplex” involve the
skull, spine, ribs, and long and short tubular bones. MPS VII patients with the most severe phenotype
have hydrops fetalis at birth and often do not survive more than a few months. Patients with mild
manifestations of MPS VII have survived into the fifth decade of life. Fifty-eight different pathogenic
mutations in the GUSB gene have been identified to date [4]. A genotype/phenotype analysis indicated
that the more severe phenotype was associated with truncating mutations.
At present, two therapeutic options are available: enzyme replacement therapy (ERT) and
hematopoietic stem cell transplantation (HSCT). For ERT, a recombinant form of human GUS
(vestronidase alpha) has been recently developed and used successfully [5], giving rise to a reduction
of urinary GAGs and an improvement of the organomegaly [6]. However, the intravenously injected
rhGUS does not cross the blood-brain-barrier and provides no effect on neurological signs, while HSCT
can bring the enzyme into the brain via its secretion from donor-derived microglial cells and prevent or
slow the neurological deterioration [7]. As learned from other MPS types, HSCT should be performed
at an early stage of these diseases in the absence of pre-existing neurological damage. To date, several
institutes have encountered HSCT in MPS VII patients. Although benefits in MPS VII treated with
HSCT have been observed regarding the somatic features of the disease, the impact on cognitive
function remains uncertain because of a lack of long-term observation of neurocognitive benefit.
We previously reported the first HSCT case with MPS VII with 2 years of follow-up post-HSCT
after the patient underwent HSCT at 12 years of age [8]. Here we have followed up this patient
over 20 years post-HSCT, and evaluated the clinical condition, including physical activity and
neurocognitive function.
2. Case Report
2.1. Diagnosis
Informed consent was obtained from her guardians. The study was approved by the ethics
committee on human research at Gifu University (IRB number; 24-176, and 26-411) and followed the
ethical principles of the Declaration of Helsinki. The patient was born at a gestational age of 38 weeks
from an uncomplicated first pregnancy of related parents, weighing 2800 g (+0.28 standard deviation
(SD)), birth length of 47.2 cm (−0.45 SD), and a head circumference of 33.4 cm (+0.29 SD). She had coarse
facial features, hepatosplenomegaly, umbilical herniation, peripheral pulmonary stenosis, ventricular
septal defect, severe neonatal jaundice, and abnormal peripheral leukocytes with striking coarse
metachromatic granules. The diagnosis was established at the age of 1 month by the demonstration of
a pronounced increase in the excretion of the urinary DS and CS and deficiency of β-glucuronidase in
leukocytes. At 6 years of age, Tomatsu et al. identified the mutation in her β-glucuronidase cDNA
producing the p.Ala619Val substitution [9]. She suffered from recurrent acute otitis media starting at
several months of age, and mild deafness was first recognized at the age of 5 years. Developmental
delay was noticed at 3 years of age, after which intellectual disability progressed gradually. Bone
deformities (lumbar gibbus, bilateral femoral caput hypoplasia) worsened steadily. She became
wheel-chair bound at 10 years of age because of gait disturbances, hip pain, and shortness of breath.
Her grasp weakened until she could not lift her handbag. She suffered recurrent upper respiratory tract
and middle ear infections. To attempt to reverse her progressive neurologic and somatic deterioration,
the parents requested that a HSCT be considered [9].
2.2. Hematopoietic Stem Cell Transplantation (HSCT)
At the age of 12 years, the patient received a successful allogeneic HSCT, from an HLA-identical,
unrelated female to correct the enzyme deficiency. The patient had full engraftment. Within 5 months
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after HSCT, the enzyme activity of the recipient’s lymphocytes increased to the normal range. No sign
of acute or chronic GVHD was observed. For the successive 31 months, β-glucuronidase activity in her
leukocytes rose to nearly normal levels, and the excretion of urinary GAGs was greatly diminished
and normalized [8].
2.3. Clinical Course after HSCT
Clinical improvement, including motor function, was well recognized. The patient became
ambulatory without aid and could even ride a bicycle and bathe alone. The recurrent infections of
the upper respiratory tract and the middle ears decreased in frequency and severity, and dyspnea on
exertion, snoring, and vertigo improved substantially [8]. At 12 years of age pre-HSCT, her intelligence
quotient (IQ) was 50, i.e., the equivalent to the developmental level of a 6-year-old, but dropped from
50 to 47 two years after the HSCT [8] (Table 1).
Table 1. Clinical manifestations.
5 Months before HSCT

15 Months after HSCT

17 Years after HSCT

21 Years after HSCT

age

12y2m

13y10m

29y11m

34y2m

Height (cm)

141.5
(−1.4 SD)

141.5
(−2.6 SD)

144.2
(−2.6 SD)

143.8
(−2.7 SD)

Weight (kg)

47.0
(+0.5 SD)

41.3
(−0.9 SD)

53.6
(+0.1 SD)

54.3
(+0.2 SD)

Body mass index

23.5

20.6

25.8

26.3

Intelligence
quotient

50

47

37

37

Coarse facies

coarse

coarse

coarse

coarse

Corneal clouding

normal

normal

normal

normal

Thoracolumbar
gibbus

abnormal

abnormal

abnormal

abnormal

Bone deformity

abnormal

abnormal

abnormal

abnormal

none

none

none

none

severe

diminished

diminished

diminished

Hepatosplenomegaly
Snoring
Deafness

moderate

moderate

moderate

moderate

Heart disease

Moderate MR
Moderate AR

Moderate MR
Moderate AR

Moderate MR
Moderate AR

Moderate MR
Moderate AR

Wheelchair

Ambulatory

Ambulatory

Ambulatory

Walking

SD: standard deviation, MR: mitral valve regurgitation, AR: aortic valve regurgitation.

At 29 years of age (17 years after HSCT), her IQ (Tanaka-Binet intelligence test V) dropped from
50 to 37 before and after HSCT (Table 1). She could walk 360 m alone in a 6 min-walk test. She has not
suffered from upper respiratory infections for several years. She couldn’t calculate change for shopping
by herself. She showed mild scoliosis, mild left ventricle hypertrophy, and moderate aortic valve
regurgitation (Table 1). Ophthalmologic examination revealed no abnormalities in the cornea or retina.
In the otolaryngological examination, tubing was inserted into the eardrum, and hearing tests showed
moderate right-sided hearing loss and left-sided mixed hearing loss, respectively. The orthopedic
assessment showed instability of the cervical spine and limited range of motion of the hip joint.
The brain MRI showed no significant difference compared with that at pre-HSCT. β-glucuronidase
activity in leukocytes was normal (Table 2). Excreted GAGs in urine were normal (Table 3).
At 34 years of age (22 years after HSCT), her IQ (Tanaka-Binet intelligence test V) was 37, i.e.,
the same as at the age of 29. She can have a simple conversation but cannot calculate change for
shopping. She retained her ambulatory mobility well. She sometimes experiences hip pain, but she
can walk alone and climb upstairs using handrails. She may feel dizzy or lightheaded when tilting
her head backward when looking up. Ophthalmologic examination revealed no abnormalities in the
cornea or retina. In the otolaryngological examination, tubing was inserted into the eardrum. Hearing
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Table 3. Urinary GAGs excretion before and after HSCT.
compared with the findings at 29 years of age.

5 Months before HSCT 15 Months after HSCT 17 Years after HSCT
Table 2. β-glucuronidase activity in lymphocytes before and after HSCT.
Urinary GAGs
44.0
18.0
12.1
(mg/g creatinine)
before HSCT
17 Years after HSCT
Control
Control
14.2 ± 6.8
11.7 ± 5.7
10.3 ± 2.0
β-glucuronidase
(nmol/mg protein/h)

ND

144.5

116.4–240.4

At 34 years of age (22 years after HSCT), her IQ (Tanaka-Binet intelligence test V) was 37, i.e.,
Arylsulfatase
the same as at
the age of 29. She can have
change for
NT a simple conversation
132.4 but cannot calculate
109.0–217.2
(nmol/mg protein/h)
shopping. She retained her ambulatory mobility well. She sometimes experiences hip pain, but she
β-hexosaminidase
can walk alone
and climb upstairs using1427
handrails. She may feel
when tilting
NT dizzy or lightheaded
562–882
(nmol/mg protein/h)
her head backward when looking up. Ophthalmologic examination revealed no abnormalities in the
ND: not detected, NT: not tested.
cornea or retina. In the otolaryngological examination, tubing was inserted into the eardrum. Hearing
tests showed moderate right-sided hearing loss and left-sided mixed hearing loss, respectively;
hearing loss on the left side
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lowerexcretion
than four
years
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Numbness
and wobbling were
Table
3. slightly
Urinary GAGs
before
and
after
HSCT.
observed during the rotation of the neck. In orthopedic assessment, the range of motion of the hip
5 Months before HSCT
15 Months after HSCT
17 Years after HSCT
joint was limited but remained unchanged. Her respiratory function showed mild restricted
Urinary
GAGs
impairment
with
a vital capacity (VC)
volume/second (FEV1.0)
of 1.5.
44.0of 69% and a forced expiratory
18.0
12.1
(mg/g creatinine)
Echocardiography showed moderate aortic regurgitation and mitral regurgitation, but cardiac
Control
14.2 ± with
6.8 the findings at11.7
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Figure 1. X-ray of the pelvis (A) pelvis at 9 years old, 3 years before HSCT, (B) pelvis at 15 years old,
Figure 1. X-ray of the pelvis (A) pelvis at 9 years old, 3 years before HSCT, (B) pelvis at 15 years old,
3 years post-HSCT, (C) pelvis at 29 years old, 17 years post-HSCT. Dysplasia of the hip acetabulum
3 years post-HSCT, (C) pelvis at 29 years old, 17 years post-HSCT. Dysplasia of the hip acetabulum
(black arrow) and deformation of the femoral head (white arrow) are observed. No obvious narrowing
(black arrow) and deformation of the femoral head (white arrow) are observed. No obvious
of the joint space has been seen.
narrowing of the joint space has been seen.
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Figure 2. Cervical spine CT at 29 years old. Occipitalization of Atlas is seen. (A) Sagittal section.
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Figure 3. Brain MRI at 34 years of age (22 years post-HSCT). (A) Sagittal T1-weighted image. (B) Axial
Figure 3. Brain MRI at 34 years of age (22 years post-HSCT). (A) Sagittal T1-weighted image. (B) Axial
T2-weighted image. The white dotted line indicates the level of axial T2-weighted image shown in (B).
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and its derivatives like brain microglia [10]. To date, 10 cases treated with HSCT have been reported
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of age [3]. One patient was of unknown age, while the remaining seven underwent HSCT before 4
years of age [3,11–14]. Three of the nine patients died within a few years after HSCT [3,12]. Five of the
seven surviving cases were reported within three years after HSCT [3,8,11,14]. It was thought that
neurological development was often well maintained in patients who had no neurological symptoms
at 3 years of age and who underwent HSCT before that time. In patients with neurological symptoms
at 3 years of age, neurological development after HSCT was not improved but was maintained at the
same or at a mildly reduced level.
Two long-term follow-up reports after HSCT were reported [3,13]. The case of transplantation
at 2 years of age and retransplantation at the age of three and a half years had scoliosis but proper
neurological development for six years [13]. The case transplanted at 3 years of age showed moderate
physical and neurological symptoms; however, the symptoms had been maintained for 12 years [3].
In this study, we have described the long-term course of the patient who received the first HSCT in
MPS VII [8]. She underwent HSCT at the age of 12 years since she had moderate intellectual disability
and difficulty walking, became wheelchair-bound, and had reduced motor skills. Two years after
HSCT, she could walk again with the improvement of physical activity and ADL. Snoring was reduced,
and respiratory function tests showed mild restrictive disorders which were maintained without
deterioration. Her intellectual level decreased but was maintained for over 20 years post-HSCT. At the
age of 12 years before HSCT, her IQ was 50, which was considered a developmental stage equivalent
to that of a 6-year-old. Twenty-two years after HSCT, her IQ had dropped from 50 to 37. Although she
did not show any improvement in development, she could live at a stage of development comparable
to that of 6-year-old, with no loss of ability gained before and after HSCT. Twenty-two years after
HSCT, changes in physical symptoms were observed due to the fusion of the first cervical vertebra and
occipital bone, worsening of cervical vertebra instability, progression of degeneration of the hip joint,
and mild deterioration of hearing.
Tomatsu and coworkers described some genotype-phenotype correlations [15]. Our patient
harbored the p.Ala619Val mutation associated with an attenuated phenotype [15]. The p.Ala619Val
mutation is of great interest since it is specific to the Japanese population [15]. The p.Ala619Val mutation
expressed 9.1% of normal cDNA in transfected COS cells. The residual activity of these expressed
mutant proteins correlated with the attenuated phenotype for those mutations [15]. Cross-Sectional
analysis showed that a higher residual β-glucuronidase enzyme activity in fibroblasts and lower GAGs
excretion in urine were associated with longer survival [16]. Another Japanese patient with MPS VII
with the p.ALa619Val mutation was diagnosed at the age of 24, but started walking at 2 years of age,
had surgery for inguinal hernia at 4 years of age, and had mild gait disturbance [8]. At the age of 14,
he had an IQ of 66 and a short stature, i.e., 125.2 cm (−5.5 SD). Until he was 30 years old, he was able to
ride a bicycle and did not experience any deterioration in his athletic ability. In MPS VII, the correlation
between genotype and phenotype has been reported [15], and p.Ala619Val is considered an attenuated
type. From the comparison of these two cases, it was considered that among the attenuated types of
p.Ala619Val, the symptoms varied among the patients. In this case, the improvement of motor function
was observed by HSCT starting even at 12 years of age, although the slow progression of neurological
findings might be due to the p.Ala619Val mutation.
Occipitalzation of the atlas is thought to be a manifestation of the so-called occipital vertebrae
(that is, incomplete segmentation between the atlantal and occipital bone) [17]. Occipitalzation of the
atlas is caused by the failure of the segmentation between the fourth occipital sclerotome (proatlas)
and the first cervical sclerotome during embryonic development [18]. The incidence of occipitalization
of the atlas ranges from 0.08% to 2.76% [19]. Occipitalization of the atlas and MPS VII may have been
merged, but the careful follow-up was necessary due to increased instability of the cervical spine.
In conclusion, the current long-term observation post-HSCT in an MPS VII patient has
demonstrated that HSCT has a therapeutic impact on motor function and ADL, and should be
considered as a therapeutic option.
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It is critical that a well-trained medical team and facility provide multi-disciplinary care with
the accompanying changes in skeletal dysplasia, hearing, visual acuity, cognitive function, ADL,
respiratory function, sleep apnea, and p valvular heart disease.
To provide further improvement in the long-term prognoses of MPS VII patients, early diagnosis
and treatment of ERT or HSCT are essential.
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